Loading...
Asgard Securities 2019-08-12T18:18:01-04:00

WHY ASGARD

ASGARD Advisory serves its clients by improving transaction terms, shortening time-to-success and minimizing management distraction in their strategic and financial transactions. We help our clients identify and evaluate a broad set of actionable strategic and financial options that are in harmony with their goals and needs.  Our team’s backgrounds set us apart from other advisors. Specifically, we have

  • Worked at top-tier investment banks on Wall Street and bring that bulge-bracket expertise to our clients. Collectively, prior to joining ASGARD, our partners have arranged and advised on more than $75 billion in transactions.
  • Held senior management roles at middle-market companies both in the U.S. and Asia
  • Made direct investments in middle-market companies

We believe that our clients deserve an advisor that considers problems and opportunities from their perspective. Our team understands these problems first-hand because we have operated companies ourselves. What differentiates ASGARD is that it strives to identify and execute transactions that make the most sense for the client. We evaluate a business and its goals from the perspective of an operator and, as a result, recommend and execute a solution that aligns with what the client wants.

ASGARD’s partners have invested in middle market companies.  Because we have seen what works over the long term, we understand what gets investors into deals on terms that work for our clients and help avoid common pitfalls that can sink deals (or companies).  We understand that valuation and interest rates aren’t the only way to get the best value in a transaction.

Cultural fit is very important to us.  We are careful to work with companies and management teams that share our values.  We find that this results in more successful outcomes and enables us to create deeper, long-term relationships.

OUR VALUE PROPOSITION

CAPITAL ADVISORY

Companies can use capital throughout their lifecycle to accelerate growth; founders and owners can partially or completely monetize what they have built by turning assets into capital.  ASGARD helps clients evaluate the many capital decisions they face.

Types of Scenarios and Forms of Capital

STRATEGIC ADVISORY SERVICES

ASGARD can provide its clients advice regarding execution of mergers or acquisitions as well as strategic planning initiatives at the Board level:

  • Assessment of Strategic Objectives
  • Target and Buyer Identification
  • Market Approach and Timing
  • Special Committee Work
  • Negotiation of Structure, Terms and Pricing
  • Managing Competitive Purchase or Sale Process
  • Diligence and Closing
ASGARD RELATIONSHIPS

The ASGARD team has deep relationships with a broad network of capital providers, that have been developed over decades rather than just years. This allows us to select and negotiate the best possible financing transaction for our clients.

  • Private Credit Funds
  • Commercial Banks
  • Finance Companies
  • Asset-Based Lenders
  • Mezzanine Funds
  • Family Offices
  • Private Equity Funds
  • Strategic Investors

TEAM

ADVISORY EXPERIENCE

The transactions shown below correspond to our partners’ experience at prior institutions.  The successful execution of these transactions is not indicative of future results at ASGARD Securities, LLC.  Furthermore, successful completion of any transaction requires a team of individuals rather than just one person. The partners of ASGARD had the support of other team members in executing each of the transactions shown below.

DEBT
$10 million
2018
Achaogen
EQUITY
$101 million
2016
Affymax, Inc.
EQUITY
$86 million
2009
Amarin Corporation
EQUITY
$70 million
2009
Anadys Pharma.
EQUITY
$18 million
2009
Anaptys Bio
EQUITY
$86 million
2017
ARINC
LBO FINANCING
$600 million
2008
Armored Auto Group
LBO FINANCING
$300 million
2011
Auspex Pharma.
EQUITY
$70 million
2014
Auspex Pharma
EQUITY
$97 million
2014
Auspex Pharma.
EQUITY
$260 million
2015
Biota Pharma
ADVISORY
$47 million
2015
Biotie Therapies
DEBT
€ 33 million
2015
Biotie Therapies
EQUITY
$64 million
2015
B/E Aerospace
DEBT
$600 million
2008
B/E Aerospace
DEBT
$475 million
2008
B/E Aerospace
DEBT
$650 million
2010
Celladon
EQUITY
$51 million
2014
Celladon
EQUITY
$44 million
2014
Centene Corporation
DEBT
$1,200 million
2016
Clearside Biomedical
EQUITY
$50 million
2016
Clearside Biomedical
EQUITY
$36 million
2016
Cogent Comm.
DEBT
$200 million
2007
Concentra
DEBT
$475 million
2004
CoLucid Pharma.
EQUITY
$55 million
2015
CoLucid Pharma
EQUITY
$75 million
2016
Covad Communications
ADVISORY
$304 million
2007
Delta Air Lines
EXIT FINANCING
$2,500 million
2007
Exar Corporation
EQUITY
$120 million
2005
Exelixis, Inc.
EQUITY
$155 million
2015
Fabrinet, Inc.
EQUITY
$98 million
2010
Freedom Group
DEBT
$200 million
2009
Genelabs Technologies
ADVISORY
$57 million
2008
Genocea Biosciences
EQUITY
$66 million
2014
Genocea Biosciences
EQUITY
$50 million
2015
Huish
DEBT
$875 million
2007
Huish
DEBT
$625 million
2008
Ingles
DEBT
$575 million
2009
Intrexon Corporation
EQUITY
$230 million
2015
Invuity, Inc.
EQUITY
$48 million
2015
Jazz Semiconductor
ADVISORY
$260 million
2006
Kenexa
EQUITY
$70 million
2005
JBS
DEBT
$700 million
2009
JBS
DEBT
$400 million
2011
JBS
DEBT
$650 million
2011
Limited Brands
DEBT
$500 million
2009
Limited Brands
DEBT
$1,000 million
2012
Loxo Oncology
EQUITY
$80 million
2014
Loxo Oncology
EQUITY
$41 million
2016
Loxo Oncology
EQUITY
$138 million
2017
MacGray
DEBT
$150 million
2005
Macy's
DEBT
$1,500 million
2010
Medtech SA
EQUITY
$15 million
2015
Medtech SA
ADVISORY
$167 million
2016
Novamed Pharma
ADVISORY
$105 million
2011
PeopleSupport
EQUITY
$96 million
2006
Polycom
ADVISORY
$220 million
2007
Qiao Xing Mobile
EQUITY
$160 million
2007
Rackspace
EQUITY
$188 million
2008
Recovery Centers of America
DEBT
$230 million
2015
RedHill Biopharma
EQUITY
$9 million
2014
Santarus
ADVISORY
$2,600 million
2013
Supervalu
DEBT
$1,000 million
2009
Surgery Partners
DEBT
$400 million
2016
Tabula Rasa
EQUITY
$59 million
2016
Toys R Us
DEBT
$1,675 million
2010
Tracon Pharma
EQUITY
$41 million
2015
Tracon Pharma
EQUITY
$25 million
2016
Tracon Pharma
EQUITY
$15 million
2016
Tokai Pharma.
EQUITY
$97 million
2014
TVN Entertainment
ADVISORY
Undisclosed
2009
Tyson Foods
DEBT
$810 million
2009
United Air Lines
DEBT
$2,100 million
2007
Victory Pharma.
EQUITY
$45 million
2009
Victory Pharma.
ADVISORY
$170 million
2009
Wendy's
DEBT
$565 million
2009
Wyle
DEBT
$175 million
2010
XO Communications
DEBT
$75 million
2008
XO Holdings
DEBT
$780 million
2008